Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vivus Inc Gets FDA Nod To Sell Diet Pill Via Retail Pharmacies-Reuters


Tuesday, 16 Apr 2013 05:43pm EDT 

Reuters reported that Vivus Inc said U.S. health regulators' approval to sell its diet pill Qsymia through retail pharmacies removed 'a major barrier' to the drug's adoption and paved the way for a direct-to-consumer campaign to be launched later this year. The U.S. Food and Drug Administration accepted Vivus's proposal to modify the REMS and allow Qsymia's sale through certified retail pharmacies.